Professor of Medical Research in Practice
Roger is an experienced drug development expert and has held numerous senior executive positions during his pharmaceutical career ushering several blockbuster drugs through FDA approval. Most recently, he served as Chief Medical Officer for Acadia Pharmaceuticals where he led the development of the first drug for the treatment of Parkinson’s Disease related Psychosis. Prior to joining Acadia, Roger served as Vice President, Pfizer Global Research and Development at the La Jolla laboratories, where he was responsible for clinical development across a broad portfolio of therapeutic areas, including oncology, virology, and ophthalmology. Earlier in his career he held senior positions at Gilead Sciences developing Tamiflu and Viread, and Norvir at Abbott Laboratories. Whilst working at Abbott he ran the first triple therapy (HAART) study for HIV as well as the seminal study describing HIV dynamics. His experience also includes portfolio and program management experience, across a spectrum of disease areas, combined with Senior Management Commercial experience in a Global Strategic Marketing Function. He has worked for large global pharmaceutical companies as well as small biotech companies. and has had experience with the US FDA and European Regulatory Agencies, as well as strategic co-development interactions, licensing activities, investor relations and financial offerings.
Roger is a Visiting Professor at the Centre for Age Related Diseases, Inst of Psychiatry, Psychology, and Neuroscience, King’s College London. He is a member of the Boards of Directors of Addex Therapeutics (Geneva) and Enterin Inc (Philadelphia), and San Diego Opera. He received his medical degree from Imperial College, Charing Cross Hospital Medical School, London.
- 1983 Charing Cross Medical School (Imperial College) MB.BS
Drug development across a range of therapeutic areas. Neurodegenerative disease and the role of neurotropic viruses in dementia.
Working with researchers/spin-out companies to access funding.
- Clinical platform for drug development for dementia at Exeter and King’s College London.